FDA: Don't drop Pfizer Z-pack; White House backs FDA bill; Digital prescriptions are all the rage;

 @FiercePharma: Momenta tops Boston Globe list of best-performing companies. Generic Lovenox made the difference. Story | Follow @FiercePharma

 @EricPFierce: What leads many employers' concerns for drug benefits? The huge jump in specialty drug expense for starters. Piece | Follow @EricPFierce

> The FDA is cautioning patients to talk their doctors and to not just stop taking Pfizer's ($PFE) so-called Z-pack antibiotic after publicity of a health study that says it can slightly raise the risk death among people with heart conditions. Story

> U.K. Health Secretary Andrew Lansley said yesterday that the country's drug regulator NICE will no longer give the National Health Service recommendations on whether drugs it is considering are cost-effective. Story

> The health ministry in Malaysia is being asked to force Abbott Laboratories ($ABT) to license its AIDS drug Kaletra HIV to a genericsmaker to lower the price there. Story

> Specialty pharmaceutical maker Sagent Pharmaceuticals is offering Irinotecan injection in two latex-free, preservative-free vials. Item

> Emergent BioSolutions has gotten the OK from the FDA to offer its vaccine for anthrax at zero, 1 and 6 months, instead of the current, zero, 12 and 18 months. Item

> The White House has thrown its support behind the FDA funding bill before Congress. Story

Biotech News

 @FierceBiotech: Gene therapy = fountain of youth in mice. Article | Follow @FierceBiotech

 @RyanMFierce: Osiris got a "first" ever nod for a stem-cell drug in Canada, but the business implications appear small. More | Follow @RyanMFierce

> The R&D revolution wants you. More

> New cloud hovers over class of 'good cholesterol' drugs. Story

> Kleiner Perkins to back early-stage biotechs with $525M fund. Article

> Allergan to enlist new hires in R&D expansion. News

> Canada hands Osiris historic approval for stem-cell drug. Report

Medical Devices News

 @FierceMedDev: As the debate over the device tax continues, a hospital group warns that devicemakers might try to game the system: Story | Follow @FierceMedDev

 @MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

 @DamianFierce: Rivals St. Jude and Medtronic are at it again, this time over study results for $STJ's EnligHTN More | Follow @DamianFierce

> Device lobby fires back at hospital group over tax 'windfall.' News

> Medtronic: DOJ closes inquiry into Infuse sales practices. Article

> Boston Sci touts long-term safety of Promus stent, despite FDA warning. Story

> Devicemakers use crowdsourcing to get patient feedback. More

And Finally... More than two-thirds of prescriptions are now being made in electronic rather than paper form. Story